Assessment of Hypersensitivity Reactions and Feasibility of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-Cell Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) at a Comprehensive Cancer Center
Interventional
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Incidence of grade III and IV hypersensitivity reactions
Every 15 minutes from start of infusion until completion
Yes
Jeffrey Jones, M.D., M.P.H.
Principal Investigator
Ohio State University
United States: Institutional Review Board
OSU-10001
NCT01206777
September 2010
February 2013
Name | Location |
---|---|
The Ohio State University Comprehensive Cancer Center | Columbus, Ohio 43210 |